US BioThrax scale-up contract could bring Emergent up to $107 million
This article was originally published in Scrip
Emergent BioSolutions has signed a contract worth up to $107 million with the US Biomedical Advanced Research and Development Authority (BARDA) to scale up manufacturing of its anthrax vaccine BioThrax, the only vaccine so far licensed by the US FDA for the prevention of anthrax infection.
You may also be interested in...
HemaQuest, a US biotech focused on developing small-molecule therapeutics for haemoglobin diseases, has expanded the Phase II programme for its lead compound, HQK-1001, in sickle cell disease with a new trial aimed at establishing safety and tolerability at higher dose levels and over a longer course of therapy.
Novartis' efforts to revive its COX-2 inhibitor lumiracoxib under a new brand name, and with the risk of hepatotoxicity that killed the drug in its original incarnation muted by a companion diagnostic, have stumbled in Europe after the company withdrew an application for centralised approval of what is now known as Joicela.
Crystallics, a new contract research organisation specialising in solid-state research and pre-formulation activities for the pharmaceutical, biotechnology and agrochemical industries, has been established in the Netherlands through a management buyout of the former Avantium Pharma business from its parent company, Avantium Holding.